Olema Pharmaceuticals Net Income Over Time
| OLMA Stock | USD 25.36 0.35 1.40% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Olema Pharmaceuticals Performance and Olema Pharmaceuticals Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. Anticipated expansion of Olema directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Olema Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Olema Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Olema's balance sheet. Smart investors calculate Olema Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Olema Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Olema Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Olema Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Olema Pharmaceuticals and related stocks such as Ventyx Biosciences, Corvus Pharmaceuticals, and Absci Corp Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VTYX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (28.2 M) | (83.7 M) | (108.4 M) | (193 M) | (135.1 M) | (121.6 M) | (127.7 M) |
| CRVS | (176 K) | (176 K) | (176 K) | (176 K) | (176 K) | (31.3 M) | (36.4 M) | (55.7 M) | (46.9 M) | (43.7 M) | (4.8 M) | (43.2 M) | (41.3 M) | (27 M) | (62.3 M) | (56.1 M) | (58.9 M) |
| ABSI | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (14.4 M) | (101 M) | (104.9 M) | (110.6 M) | (103.1 M) | (92.8 M) | (97.4 M) |
| RGNX | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (4 M) | (22.8 M) | (63 M) | (73.2 M) | 99.9 M | (94.7 M) | (111.2 M) | 127.8 M | (280.3 M) | (263.5 M) | (227.1 M) | (204.4 M) | (194.2 M) |
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.8 M) | (147 M) | (180.8 M) | (243.4 M) | (234 M) | (229.4 M) | (179.8 M) | (56.5 M) | (50.9 M) | (53.4 M) |
| PRTA | (12.5 M) | (29.7 M) | (41.4 M) | (41 M) | (7.2 M) | (80.6 M) | (160.1 M) | (153.2 M) | (155.6 M) | (77.7 M) | (111.1 M) | 67 M | (116.9 M) | (147 M) | (122.3 M) | (110.1 M) | (115.6 M) |
| VSTM | (786 K) | (13.7 M) | (32 M) | (41.2 M) | (53.4 M) | (57.9 M) | (36.4 M) | (67.8 M) | (72.4 M) | (149.2 M) | (67.7 M) | (71.2 M) | (73.8 M) | (87.4 M) | (130.6 M) | (117.6 M) | (111.7 M) |
| KALV | (2.1 M) | (2.1 M) | (2.1 M) | (5.7 M) | (13.4 M) | (24.8 M) | (18.6 M) | (15.8 M) | (20.8 M) | (29.1 M) | (46.2 M) | (82.3 M) | (92.9 M) | (126.6 M) | (183.4 M) | (24.8 M) | (26.1 M) |
| FDMT | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (9.6 M) | (49.3 M) | (56.7 M) | (68.3 M) | (101.1 M) | (100.8 M) | (160.9 M) | (144.8 M) | (137.5 M) |
| LXRX | (12.5 M) | (116.2 M) | (110.2 M) | (104.1 M) | (100.3 M) | (4.7 M) | (141.4 M) | (129.1 M) | (120.5 M) | 130.1 M | (58.6 M) | (87.8 M) | (101.9 M) | (177.1 M) | (200.4 M) | (180.4 M) | (171.3 M) |
Olema Pharmaceuticals and related stocks such as Ventyx Biosciences, Corvus Pharmaceuticals, and Absci Corp Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Olema Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Olema Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Olema Pharmaceuticals | OLMA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 780 Brannan Street, |
| Exchange | NASDAQ Exchange |
USD 25.36
Check out Olema Pharmaceuticals Performance and Olema Pharmaceuticals Correlation. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Olema Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.